Blood viscosity reduction

Blood viscosity reduction is a physiological or therapeutic process that decreases the internal resistance of blood to flow, thereby improving microcirculation and systemic hemodynamics. It is not a single molecular target, such as a receptor or enzyme, but rather a complex hemorheological outcome influenced by factors including hematocrit, red blood cell deformability, and the concentration of plasma proteins like fibrinogen. Increased blood viscosity is associated with hyperviscosity syndromes and various cardiovascular conditions, where it contributes to stasis, endothelial shear stress, and an elevated risk of thrombosis. Therapeutic agents like pentoxifylline are used to reduce viscosity by improving the flexibility of red blood cells, which allows them to pass more easily through narrow capillaries. Monitoring and managing blood viscosity is essential in the treatment of peripheral artery disease and other circulatory disorders to ensure adequate tissue oxygenation.

Other names

Hemorheologic improvementReduced blood viscosityBlood thinning (non-specific)Hemorheology

Drugs achieve blood viscosity reduction by increasing erythrocyte deformability, decreasing fibrinogen concentration, inhibiting platelet aggregation, or reducing hematocrit levels through hemodilution or myelosuppression.